INSPRA (eplerenone) Product Monograph. Page 2 of Table of This leaflet is a summary and will not tell you everything about INSPRA. X. Package leaflet: Information for the patient. Eplerenone 25 mg film-coated tablets. Eplerenone 50 mg film-coated tablets. Eplerenone. Read all of this leaflet . Easy to read FDA package insert, drug facts, dosage and administration, and adverse effects for Inspra (eplerenone).
|Published (Last):||9 July 2013|
|PDF File Size:||14.9 Mb|
|ePub File Size:||4.66 Mb|
|Price:||Free* [*Free Regsitration Required]|
The ADRs were judged serious in 11 of 26 patients Table 3. In contrast, the percentage of patients with serum potassium values over 5.
Subject Characteristics Among the 3, patients included in the safety analysis, The elimination half-life of Eplerenome is approximately 3 to 6 hours.
Therefore, we concluded that it is not necessary to call for special attention or implement new measures to ensure safety for concomitant use of eplerenone and other antihypertensive drugs. The risk for cardiovascular events has been shown to be high among patients with hypertensive conditions, particularly among those who have comorbidities such as diabetes, chronic kidney disease CKDmetabolic syndrome, cerebrovascular disorders, or organ dysfunction including heart disease.
The physicians in charge were encouraged to consult the Guidelines for the Management of Ibsert to determine the severity of hypertension in a comprehensive manner. Published studies of eplerenone for hypertension used doses up to mgd despite the package insert limiting doses to 50 mg twice daily, reflecting concerns over hyper kalemia in patients with.
The reason for the gradual decrease in BP and the antihypertensive effects of eplerenon may involve the complex mechanism of action of the drug. The finding that eplerenone gradually reduced BP over months is consistent with a previous report [ 9 ].
Eplerenone binds to the mineralocorticoid receptor and blocks the binding of aldosterone, a component of the renin-angiotensin-aldosterone-system RAAS. The observation period was 12 weeks and began upon initiation of treatment.
For Patients Treated for Hypertension. Eplerenone metabolism is primarily mediated via CYP3A4. In the analysis of the binary data, the frequencies and incidence of AEs were calculated.
Heart Failure amlodipinelisinoprilfurosemidecarvedilolmetoprololdiltiazemLasixspironolactonewarfarindigoxinhydralazineMore Find information about a drug food and drug administration.
International Journal of Hypertension
The incidence of adverse drug reactions was 2. Serum potassium levels during eplerenone treatment relative to baseline levels. Control of high blood pressure should be part of comprehensive CV risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. However, considering that, on average, clinically significant effectiveness against hypertension was observed during the observation period, the effectiveness of eplerenone as an antihypertensive drug was shown under the conditions in which it is currently used.
However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions.
Third, because there were no exclusion criteria in this study, patients with severe conditions such as active malignancy were not excluded, which might have affected the safety and efficacy parameters.
The mean duration of eplerenone treatment was days, and the median was The incidence of hypotension among patients prescribed antihypertensive drugs in addition to eplerenone was considered as not high and the symptoms were improved.
Clinicians should pay careful attention to the contraindications listed on the package insert when prescribing drugs and conducting regular monitoring of serum potassium levels.
It occurs because the heart is no longer able to maintain normal venouscapillary pressures, cardiac output, andor systemic blood pressure.
Between May and Aprilwe conducted a PMS that targeted hypertensive patients in Japan who had not previously been treated with eplerenone. The concentration of Eplerenone in human breast milk after oral administration is unknown. Elevated systolic or diastolic pressure causes increased CV risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit.
Patients on moderate CYP3A inhibitors that cannot be avoided should have their dose of Eplerenone reduced.
The most frequent serious adverse events were hyperkalemia 8 cases followed by renal impairment 3 cases. Even the package insert does not reflect its use in children, although it was updated in Hypertension is a major public health issue in many countries.
eplerenone Entire Monograph – Epocrates Online
This surveillance has several limitations. Aldosterone binds to mineralocorticoid receptors in both epithelial e. No teratogenic effects were seen in rats or rabbits, although decreased body weight in maternal rabbits and increased rabbit fetal resorptions and post-implantation loss were observed at the highest administered dosage. All the deaths were judged as not attributable to eplerenone.
If hyperkalemia develops, standard treatment should be initiated. Eplerenone metabolism is predominantly mediated via CYP3A. Table of Contents Alerts. In patients with hypertension receiving a moderate CYP3A inhibitor, initiate at 25 mg once daily.
Food and drug administration new hampshire avenue silver spring, md Adverse events occurred at a similar rate regardless of age, gender, or race. The pharmacokinetics of Eplerenone did not differ significantly between males and females.
Serum lithium levels should be monitored frequently if Eplerenone eplerwnone administered concomitantly with lithium.
Because many drugs are excreted in human milk and because of the unknown potential for adverse effects on the nursing infant, decide whether to discontinue nursing or discontinue the drug. There was no significant change in average heart rate among patients treated with Eplerenone in the combined clinical studies.
Online convert pdf to tiff application software utility. Administration of any concomitant treatment including other antihypertensive drugs was not restricted. Both peak plasma levels C max and area under the curve AUC are dose proportional for doses of 25 mg to mg and less than proportional at doses above mg. This organ damage includes ventricular remodeling [ 1516 ], renal impairment [ 17 — 19 ], and vascular endothelial dysfunction [ 20 ].
Online convert pdf to tiff application software utility html. There was no tendency for the incidence of hyperkalemia to increase when eplerenone was used with either thiazide diuretics or loop diuretics. The rates increased with increasing duration of therapy.